148 related articles for article (PubMed ID: 37232070)
21. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
22. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Tsuburaya A; Morita S; Kodera Y; Kobayashi M; Shitara K; Yamaguchi K; Yoshikawa T; Yoshida K; Yoshino S; Sakamoto J
BMC Cancer; 2012 Jul; 12():307. PubMed ID: 22824079
[TBL] [Abstract][Full Text] [Related]
23. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
Arkenau HT; Graeven U; Kubicka S; Grothey A; Englisch-Fritz C; Kretzschmar A; Greil R; Freier W; Seufferlein T; Hinke A; Schmoll HJ; Schmiegel W; Porschen R;
Clin Colorectal Cancer; 2008 Jan; 7(1):60-4. PubMed ID: 18279579
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Shen L; Li J; Xu J; Pan H; Dai G; Qin S; Wang L; Wang J; Yang Z; Shu Y; Xu R; Chen L; Liu Y; Yu S; Bu L; Piao Y
Gastric Cancer; 2015 Jan; 18(1):168-76. PubMed ID: 24557418
[TBL] [Abstract][Full Text] [Related]
26. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
27. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE).
Ryu MH; Lee KH; Shen L; Yeh KH; Yoo C; Hong YS; Park YI; Yang SH; Shin DB; Zang DY; Kang WK; Chung IJ; Kim YH; Ryoo BY; Nam BH; Park YS; Kang YK
Cancer Med; 2023 Apr; 12(7):7784-7794. PubMed ID: 36515003
[TBL] [Abstract][Full Text] [Related]
29. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
[TBL] [Abstract][Full Text] [Related]
30. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.
Hall PS; Swinson D; Cairns DA; Waters JS; Petty R; Allmark C; Ruddock S; Falk S; Wadsley J; Roy R; Tillett T; Nicoll J; Cummins S; Mano J; Grumett S; Stokes Z; Kamposioras KV; Chatterjee A; Garcia A; Waddell T; Guptal K; Maisey N; Khan M; Dent J; Lord S; Crossley A; Katona E; Marshall H; Grabsch HI; Velikova G; Ow PL; Handforth C; Howard H; Seymour MT;
JAMA Oncol; 2021 Jun; 7(6):869-877. PubMed ID: 33983395
[TBL] [Abstract][Full Text] [Related]
32. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
33. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
Li WZ; Lv X; Hu D; Lv SH; Liu GY; Liang H; Ye YF; Yang W; Zhang HX; Yuan TZ; Wang DS; Lu N; Ke LR; Tang WB; Tong LH; Chen ZJ; Liu T; Cao KJ; Mo HY; Guo L; Zhao C; Chen MY; Chen QY; Huang PY; Sun R; Qiu F; Luo DH; Wang L; Hua YJ; Tang LQ; Qian CN; Mai HQ; Guo X; Xiang YQ; Xia WX
JAMA Oncol; 2022 May; 8(5):706-714. PubMed ID: 35323856
[TBL] [Abstract][Full Text] [Related]
34. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
36. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
Ajani JA; Abramov M; Bondarenko I; Shparyk Y; Gorbunova V; Hontsa A; Otchenash N; Alsina M; Lazarev S; Feliu J; Elme A; Esko V; Abdalla K; Verma U; Benedetti F; Aoyama T; Mizuguchi H; Makris L; Rosati G;
Ann Oncol; 2017 Sep; 28(9):2142-2148. PubMed ID: 28911091
[TBL] [Abstract][Full Text] [Related]
37. Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer.
Ustaalioglu BBO; Bilici A; Tilki M; Surmelioglu A; Erkol B; Figen M; Uyar S
J Cancer Res Ther; 2018 Sep; 14(Supplement):S736-S741. PubMed ID: 30249896
[TBL] [Abstract][Full Text] [Related]
38. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
Park IH; Im SA; Jung KH; Sohn JH; Park YH; Lee KS; Sim SH; Park KH; Kim JH; Nam BH; Kim HJ; Kim TY; Lee KH; Kim SB; Ahn JH; Lee S; Ro J
Cancer Res Treat; 2019 Jan; 51(1):43-52. PubMed ID: 29458237
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Meulendijks D; de Groot JW; Los M; Boers JE; Beerepoot LV; Polee MB; Beeker A; Portielje JE; Goey SH; de Jong RS; Vanhoutvin SA; Kuiper M; Sikorska K; Pluim D; Beijnen JH; Schellens JH; Grootscholten C; Tesselaar ME; Cats A
Cancer; 2016 May; 122(9):1434-43. PubMed ID: 26970343
[TBL] [Abstract][Full Text] [Related]
40. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
